Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
用户r-lcVIN14xaE
1个月前
65
50
已关闭
DOI: 10.1016/S2468-1253(21)00109-6
文献链接: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00109-6/abstract
其他信息:
需要的是补充材料！
发表期刊：The Lancet Gastroenterology & Hepatology
